Anti-aging drugs extend lifespan in mice, spark hope for human longevity Excerpt (117 characters):
In a quietly remarkable advance from European researchers, a pair of existing cancer drugs rapamycin and trametinib have been shown to extend the lifespans of mice by up to 35 percent.
The study, conducted by scientists at the Max Planck Institute for Biology of Ageing in Germany, offers promising evidence that longevity-enhancing interventions might not only lengthen life but also delay the onset of age-related diseases.
While rapamycin has long been studied for its life-extending potential in animals, trametinib was previously shown to increase the lifespan of fruit flies.
The real revelation, however, came when the two drugs were combined. Mice given both compounds not only lived longer but also aged more gracefully exhibiting fewer tumours, reduced inflammation in multiple organs, and better heart and muscle health in old age.
Female mice experienced median lifespan increases of nearly 35 percent, with males not far behind at 27.4 percent. Maximum lifespan gains were similarly impressive.
Researchers attribute the effect to the drugs' distinct points of action within the Ras/Insulin/TOR pathway, which regulates growth and aging.
Notably, no additional side effects were observed when the drugs were used together—an encouraging sign for future human applications.
Linda Partridge, a geneticist and co-senior author of the study, noted that while humans shouldn't expect to add decades to their lifespans, the real value might lie in extending the period of life lived in good health.
The study adds to a growing body of research suggesting that aging is not only modifiable but potentially treatable. With both drugs already approved for human use in the US and EU, clinical trials to test their anti-aging effects could begin soon.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Business Recorder
2 days ago
- Business Recorder
Collaborative efforts required to reduce smoking rates faster
Pakistan stands at a critical juncture in its efforts to reduce smoking. Rapid progress will require a united front—governments, businesses, health organisations, and individuals working in close collaboration. Without strong leadership and sustained public — private partnerships, the vision of a smoke-free future will remain out of reach. Governments must recognise the important role of smoke-free products in reducing tobacco-related harm. Embracing science and innovation, along with clear regulations that prevent youth uptake, enables them to make informed adult choices. Addressing misinformation and fostering dialogue between public and private stakeholders is equally crucial. A powerful example of this approach can be seen in Sweden. By embracing smoke-free alternatives alongside conventional tobacco control efforts, Sweden has rapidly reduced its smoking rates and is now poised to become Europe's first smoke-free country, with fewer than 5% of adults smoking. This forward-thinking model has led Sweden to achieve one of the lowest smoking rates in the developed world. Karl Fagerström, a clinical psychologist from Spain, further endorsed the Swedish philosophy, stating: 'Public health benefits of the Swedish strategy are 'very high.' Compared to the rest of the European Union, Sweden has 44% fewer tobacco-related deaths. Data shows that, although Sweden has a level of nicotine consumption similar to the European average, the country has a 41% lower incidence of lung cancer.' Pakistan can draw lessons from Sweden's success. Encouraging the use of scientifically backed smoke-free products has the potential to offer a less harmful path for adult smokers and reduce the long-term health burden on the country's healthcare system. Abu Bakar Kareem (Karachi) Copyright Business Recorder, 2025
Express Tribune
3 days ago
- Express Tribune
Sanofi's $9.5B acquisition of Blueprint Medicines strengthens rare immunology portfolio
In a major move underscoring its ambition to lead in rare diseases and immunology, French pharmaceutical giant Sanofi announced its plan to acquire US-based Blueprint Medicines for up to $9.5 billion. The deal was announced by a press release on Sanofi's website. It is the largest by a European healthcare company this year and will see Sanofi paying $129 per share in cash, a significant premium that sent Blueprint's stock soaring in premarket trading. Blueprint Medicines, known for its specialty in treating systemic mastocytosis a rare blood disorder marked by the overproduction of mast cells brings to Sanofi a strong foothold in a niche yet critical area of medicine. The acquisition adds the FDA-approved drug Ayvakit, the only treatment for advanced systemic mastocytosis, to Sanofi's growing immunology portfolio. Sanofi CEO Paul Hudson framed the deal as a strategic leap forward, enhancing the company's pipeline and reinforcing its transformation into a global leader in immunology. We announced an agreement to acquire Blueprint Medicines, a biopharmaceutical company specializing in systemic mastocytosis, a rare immunological disease, and other KIT-driven diseases. — Sanofi (@sanofi) June 2, 2025 With a promising pipeline including next-generation therapies like elenestinib and BLU-808, the acquisition fits into Sanofi's broader ambition of innovation despite recent setbacks, including a failed lung disease drug trial. Industry analysts from JP Morgan praised the acquisition for its strategic and financial merits, forecasting Ayvakit could generate $2 billion in annual sales by 2030. Sanofi's ongoing spree of acquisitions, including Vigil Neuroscience and Inhibrx, signals a company doubling down on R&D investments to reshape its future. The acquisition aligns with Sanofi's broader strategy to invest heavily in US manufacturing and research, tapping into incentives and momentum driven by recent government policies. With Blueprint Medicines now joining its portfolio, Sanofi cements its stake in cutting-edge immunology treatments and rare disease therapies, positioning itself for long-term growth in a competitive pharmaceutical landscape.
Express Tribune
29-05-2025
- Express Tribune
Anti-aging drugs extend lifespan in mice, spark hope for human longevity Excerpt (117 characters):
In a quietly remarkable advance from European researchers, a pair of existing cancer drugs rapamycin and trametinib have been shown to extend the lifespans of mice by up to 35 percent. The study, conducted by scientists at the Max Planck Institute for Biology of Ageing in Germany, offers promising evidence that longevity-enhancing interventions might not only lengthen life but also delay the onset of age-related diseases. While rapamycin has long been studied for its life-extending potential in animals, trametinib was previously shown to increase the lifespan of fruit flies. The real revelation, however, came when the two drugs were combined. Mice given both compounds not only lived longer but also aged more gracefully exhibiting fewer tumours, reduced inflammation in multiple organs, and better heart and muscle health in old age. Female mice experienced median lifespan increases of nearly 35 percent, with males not far behind at 27.4 percent. Maximum lifespan gains were similarly impressive. Researchers attribute the effect to the drugs' distinct points of action within the Ras/Insulin/TOR pathway, which regulates growth and aging. Notably, no additional side effects were observed when the drugs were used together—an encouraging sign for future human applications. Linda Partridge, a geneticist and co-senior author of the study, noted that while humans shouldn't expect to add decades to their lifespans, the real value might lie in extending the period of life lived in good health. The study adds to a growing body of research suggesting that aging is not only modifiable but potentially treatable. With both drugs already approved for human use in the US and EU, clinical trials to test their anti-aging effects could begin soon.
